Has the first year of the COVID-19 pandemic reversed the trends in CV mortality between 1999 and 2019 in the United States?


Journal

European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796

Informations de publication

Date de publication:
21 06 2023
Historique:
received: 01 09 2022
revised: 29 10 2022
accepted: 25 11 2022
medline: 23 6 2023
pubmed: 29 11 2022
entrez: 28 11 2022
Statut: ppublish

Résumé

Although cardiovascular (CV) mortality increased during the COVID-19 pandemic, little is known about how these patterns varied across key subgroups, including age, sex, and race and ethnicity, as well as by specific cause of CV death. The Centers for Disease Control WONDER database was used to evaluate trends in age-adjusted CV mortality between 1999 and 2020 among US adults aged 18 and older. Overall, there was a 4.6% excess CV mortality in 2020 compared to 2019, which represents an absolute excess of 62 802 deaths. The relative CV mortality increase between 2019 and 2020 was higher for adults under 55 years of age (11.9% relative increase), vs. adults aged 55-74 (7.9% increase), and adults 75 and older (2.2% increase). Hispanic adults experienced a 9.4% increase in CV mortality (7400 excess deaths) vs. 4.3% for non-Hispanic adults (56 760 excess deaths). Black adults experienced the largest % increase in CV mortality at 10.6% (15 477 excess deaths) vs. 3.5% increase (42 907 excess deaths) for White adults. Among individual causes of CV mortality, there was an increase between 2019 and 2020 of 4.3% for ischaemic heart disease (32 293 excess deaths), 15.9% for hypertensive disease (13 800 excess deaths), 4.9% for cerebrovascular disease (11 218 excess deaths), but a decline of 1.4% for heart failure mortality. The first year of the COVID pandemic in the United States was associated with a reversal in prior trends of improved CV mortality. Increases in CV mortality were most pronounced among Black and Hispanic adults.

Identifiants

pubmed: 36442154
pii: 6849964
doi: 10.1093/ehjqcco/qcac080
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

367-376

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

Ofer Kobo (O)

Department of Cardiology, Hillel Yaffe Medical Center, Hadera 38100, Israel.
Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Stoke-on-Trent ST5 5BG, UK.

Dmitry Abramov (D)

Division of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, CA 92354, USA.

Marat Fudim (M)

Department of Medicine, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27710, UK.

Garima Sharma (G)

Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Diseases, Johns Hopkins School of Medicine, Baltimore 21287, UK.

Vijay Bang (V)

Department of cardiology, Lilavati Hospital and Research Center, Mumbai 400040, India.

Ashish Deshpande (A)

Department of cardiology, Oriion Citicare Hospital, Aurangabad 431005, India.

Rishi K Wadhera (RK)

Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Mamas A Mamas (MA)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Stoke-on-Trent ST5 5BG, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH